What is liver directed therapy?
Colorectal cancer can spread to other parts of your body through your blood or lymphatic system. The liver is the most common site of metastasis in patients with colorectal cancer, due to the blood supply that exists between the large intestine and the liver.
While liver metastasis can be very challenging to stop, there are options to consider for treatment.
Surgery can play an important role in treating liver metastasis for many patients. However, not everyone is a candidate for liver surgery.
Because liver directed therapies are localized and target just the tumor, much of the surrounding tissue is spared. Many of these therapies are minimally invasive and have a short recovery time.
Read moreHAI Therapy
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.
Don Shippey was 55 years old in 2016 when he decided he’d been putting off his colonoscopy long enough.
Takeda has announced U.S. Food and Drug Administration (FDA) approval of FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.